Commemorating World Malaria Day, Malaria No More India with the Government of Odisha co-organized an elaborate event in Bhubaneshwar, Odisha. The theme, in line with WHO’s global theme, was ‘Harnessing innovation to reduce malaria and save lives’ and the event saw dialogue around current and
Prime Minister Narendra Modi nudges startups, entrepreneurs, and industry to increase investment for innovation in Ayush Prime Minister Narendra Modi deep dived into India’s expertise in the field of traditional and integrative medicine India will go to the world, and the entire world will come to India:
Today, Shri Sarbananda Sonowal, Union Minister, Ayush and Vaidya Rajesh Kotecha, Secretary, Ayush visited the site in Jamnagar for the groundbreaking of the WHO Global Centre for Traditional Medicine. Two weeks ago, the Ministry of Ayush had signed the host Country Agreement with World Health
The Government of India is all set to launch a special door-to-door TB screening initiative on 24 March 2022, globally observed as World TB Day. Under this initiative, over the next two to three weeks, health workers will be visiting the vulnerable population that is
A staggering 65% of the Tuberculosis cases in India are in the 15-45 age group Mortality numbers due to Tuberculosis in India are more than other South Asian neighbours a Mumbai based health-tech startup, supported by the Department of Science & Technology, Govt of India, healthcare veterans
~ The healthy ‘You’ can keep others happy ~ IN THE WORDS OF COCO CHANEL, “THE MOST COURAGEOUS ACT IS STILL TO THINK FOR YOURSELF. ALOUD.” Women Indian Chamber of Commerce and Industry (WICCI) organized the seminar on prevention of cancer in women & role of robotic
Over 23,282 nurses worldwide vying for grand prize of $250,000 Nurses from over 184 countries competing in global awards honoring frontline workers So far, around 4334 nurses from India have entered the prestigious Award following one of the toughest healthcare crises in recent history Global
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), R-Pharm group and AstraZeneca announce interim results of phase II clinical trials to evaluate the safety and immunogenicity of the combined use of AstraZeneca's vaccine and the first component of the Sputnik V coronavirus vaccine
* Mild symptoms for those who are fully vaccinated * Not much prevalent in children * Cases almost equal in men and women Severity in Covid-19 is much lesser in Omicron variant when compared to Delta variant. Those who are fully vaccinated with both the doses need not
COVAXINÒ is the one of the first COVID-19 vaccines in the world to generate data in 2-18 year age group. Phase II/III, Open-Label, Multi-centre Study was conducted to evaluate the Safety, Reactogenicity, and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in healthy children
